Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 65.58M | 65.10M | 60.73M | 60.48M | 56.49M |
| Gross Profit | -65.58M | -65.10M | -60.73M | -60.48M | -56.49M |
| SG&A Expenses | 25.80M | 24.37M | 23.13M | 20.47M | 20.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.40M | 112.49M | 106.88M | 101.01M | 96.94M |
| Operating Income | -114.40M | -112.49M | -106.88M | -101.01M | -96.94M |
| Income Before Tax | -148.70M | -152.87M | -139.66M | -105.70M | -110.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -148.70 | -152.87 | -139.66 | -105.70 | -110.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -148.70M | -152.87M | -139.66M | -105.70M | -110.78M |
| EBIT | -114.40M | -112.49M | -106.88M | -101.01M | -96.94M |
| EBITDA | -107.21M | -105.28M | -99.65M | -93.57M | -89.22M |
| EPS Basic | -1.26 | -1.34 | -1.26 | -1.01 | -1.07 |
| Normalized Basic EPS | -0.61 | -0.64 | -0.63 | -0.61 | -0.59 |
| EPS Diluted | -1.26 | -1.34 | -1.26 | -1.01 | -1.07 |
| Normalized Diluted EPS | -0.61 | -0.64 | -0.63 | -0.61 | -0.59 |
| Average Basic Shares Outstanding | 473.81M | 450.44M | 434.47M | 418.66M | 413.68M |
| Average Diluted Shares Outstanding | 473.81M | 450.44M | 434.47M | 418.66M | 413.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |